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Abstract Rho kinase is known to control smooth muscle con-
tractility by phosphorylating the 110 kDa myosin-targetting
subunit (MYPT1) of the myosin-associated form of protein
phosphatase 1 (PP1M). Phosphorylation of MYPT1 at
Thr695 has previously been reported to inhibit the catalytic
activity of PP1. Here, we show that the phosphorylation of
Thr850 by Rho kinase dissociates PP1M from myosin, provid-
ing a second mechanism by which myosin phosphatase activity is
inhibited. * 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Protein phosphatase 1 (PP1), one of the major serine/threo-
nine-speci¢c protein phosphatases of eukaryotic cells, is regu-
lated by a variety of targetting subunits that direct the cata-
lytic subunit (PP1C) to particular subcellular locations,
modify its substrate speci¢city and allow its activity to be
regulated in a substrate-speci¢c manner in response to extra-
cellular signals (reviewed in [1^3]). For example a glycogen-
associated form present in muscle, termed PP1G, comprises
PP1C complexed to a glycogen-binding GM subunit. [4]. Phos-
phorylation of the GM subunit by cyclic AMP-dependent pro-
tein kinase triggers the dissociation of PP1C from GM. This
releases PP1 from glycogen, which is thought to inhibit the
dephosphorylation of glycogen-bound substrates (glycogen
phosphorylase and glycogen synthase) [5,6].
The form of PP1 associated with myosin (PP1M) consists of
PP1C complexed to a myosin-targetting subunit, termed
MYPT1 (myosin phosphatase targetting 1) or M110, which is
itself complexed to another protein, termed M21 [7^10]. The
binding site for PP1C is close to the N-terminus of MYPT1
[9], a myosin-binding site is situated between residues 714 and
933, while the C-terminal 72 residues of MYPT1 bind the M21
subunit [10].
The Rho-activated kinase (termed ROK or ROCK) is
thought to control the level of phosphorylation of the myosin
P-light chain [11^13]. One way in which this is thought to
occur is via the ROCK-catalysed phosphorylation of
MYPT1, which is reported to inhibit PP1M activity and so
increase the level of phosphorylation of the myosin P-light
chain. This is believed to induce the contraction of smooth
muscle and to induce stress ¢bre formation in non-muscle
cells [14]. ROCK has been reported to phosphorylate
MYPT1 at Thr695/Thr697 (chicken/rat), Ser 849/854 and
Thr850/855 [13]. Based on experiments in which Thr695 and
Thr850 were mutated to Ala, the phosphorylation of Thr695
appears to be required and su⁄cient for the inhibition of
PP1M catalytic activity [15]. However, the role that phosphor-
ylation of Thr850 and Ser849 may play in the regulation of
PP1M function has not yet been determined. Here, we show
that the phosphorylation of PP1M by the ROCK-II/ROKK
isoform [16] dissociates PP1M from myosin and implicates
Thr850 in this process.
2. Materials and methods
2.1. Materials
Oligonucleotides were from Oswell (Cambridge, UK), enzymes
from Roche (Basel, Switzerland), baculovirus expression kit from
Life Technologies (Paisley, UK), Vydac 218TP54 C18 column from
the Separations Group (Hesperia, CA, USA), and okadaic acid and
microcystin-LR from Calbiochem-Novabiochem Corp. (La Jolla, CA,
USA). All other chemicals were from BDH Chemicals or Sigma
(Poole, UK). Smooth muscle PP1M and myosin were puri¢ed from
chicken gizzard [7,9] and residues 714^1004 of chicken gizzard
MYPT1 were expressed as a maltose-binding protein (MBP) fusion
protein [7].
2.2. Antibody production
The PP1M holoenzyme was injected into sheep and the antisera
a⁄nity-puri¢ed on Sepharose to which the C-terminal fragment com-
prising residues 714^1004 of MYPT1 had been attached covalently, in
order to obtain antibodies that recognise the MYPT1 subunit specif-
ically [7]. Antibodies that recognise chicken gizzard MYPT1 only
when it is phosphorylated at Thr850 were raised against the peptide
Glu-Lys-Arg-Arg-Ser-pThr-Gly-Val-Ser-Phe-Trp (where pThr denotes
phosphothreonine). The peptides were conjugated separately to bo-
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vine serum albumin (BSA) and keyhole limpet haemocyanin, mixed
and injected into sheep at Diagnostics Scotland (Penicuik, UK). The
antisera were a⁄nity-puri¢ed on peptide CH-Sepharose columns.
2.3. Construction of vectors and expression of ROCK-II in Sf9 cells
The plasmid pGEX4T-ROKK1543 (a generous gift from Dr Louis
Lim, IMCB, Singapore) encoding the catalytic domain of rat ROCK-




A baculovirus vector was generated according to the manufactur-
er’s instructions (Life Technologies, Paisley, UK) and used to infect
insect cells. The cells were collected, lysed in bu¡er containing 50 mM
Tris^HCl pH 8.5, 10 mM 2-mercaptoethanol, 1 mM phenylmethylsul-
phonyl £uoride and 1% Nonidet P40. The 6-His-tagged protein was
then puri¢ed from the extracts by a⁄nity chromatography on nickel-
nitrilotriacetate agarose. The His-ROCK-II is available from Upstate
(www.upstate.com).
2.4. Phosphorylation by ROCK-II
0.5 WM PP1M or 1 WM MBP-MYPT1[714^1004] were incubated for
10 min with 50 nM ROCK-II for the myosin-binding assays, or
0.2 WM PP1M was incubated with 0.5 nM ROCK-II to study the
e¡ect of phosphorylation on PP1M activity. The phosphorylation re-
actions were carried out in 50 mM Tris^HCl, pH 7.5, 0.1 mM EGTA,
0.1% (by vol.) 2-mercaptoethanol, 0.03% (by mass) Brij 35, 10 mM
Mg acetate and either 200 WM ATP[QS] or 100 WM ATP. The thio-
phosphorylated PP1M or phosphorylated MBP-M110(714^1004) were
then diluted in bu¡er A (50 mM Tris^HCl, 0.1 mM EGTA, 0.1% (by
vol.) 2-mercaptoethanol, 0.03% (by mass) Brij 35, 1 mg/ml BSA) and
used to study the binding to myosin or to measure PP1M activity.
2.5. Protein phosphatase assays
These were carried out by measuring the dephosphorylation of 32P-
labelled myosin P-light chain or 32P-labelled glycogen phosphorylase
as described [7].
2.6. Myosin-binding experiments
These were performed as described [10]. Brie£y, myosin (0.5 mg/ml)
in 10 mM HEPES, pH 7.5, 50 mM KCl, 5 mM MgCl2, 0.1% (by vol.)
2-mercaptoethanol was mixed with PP1M or MBP-MYPT1[714^1004]
that had been phosphorylated with or without ROCK-II. After incu-
bation for 30 min at 0‡C, the suspensions were centrifuged for 2 min
at 13 000Ug and the supernatants collected. The myosin pellets were
then washed twice in 10 mM HEPES, pH 7.5, 50 mM KCl, 5 mM
MgCl2, 0.1% (by vol.) 2-mercaptoethanol, before redissolving to the
same volume as the supernatant fraction in 50 mM Tris^HCl, pH 7.5,
0.1 mM EGTA, 0.03% (by mass) Brij 35, 0.6 M NaCl, 0.1% (by vol.)
2-mercaptoethanol. Aliquots of the supernatant and the resuspended
Fig. 1. ROCK-II phosphorylates the MYPT1 subunit of chicken gizzard PP1M at Thr695 and Thr850. A: The chicken gizzard PP1M complex
(1 WM) was incubated for 15 min with 50 nM ROCK-II in 50 mM Tris^HCl, pH 7.5, 0.1 mM EGTA, 0.1% (by vol.) 2-mercaptoethanol,
0.03% (by mass) Brij 35, 1 WM okadaic acid, 10 mM Mg acetate and 100 WM [32P]ATP, then denatured in SDS, separated by SDS^PAGE and
either stained with Coomassie blue (left hand gel) or autoradiographed (right hand gel). B: The 32P-labelled band from A was excised, eluted
from the gel piece and digested with trypsin as described [22]. The supernatant containing s 90% of the 32P radioactivity was chromatographed
on a Vydac 218TP54 C18 column equilibrated with 0.1% (by vol.) tri£uoroacetic acid and developed with a linear acetonitrile gradient (broken
line). The 32P radioactivity is shown by the full line. The £ow rate was 0.8 ml/min, and fractions of 0.4 ml were collected. C: The 32P-labelled
phosphopeptide from B was subjected to solid phase sequencing and 32P radioactivity released after each cycle of Edman degradation was mea-
sured by Cerenkov counting to identify the sites of phosphorylation [22].
FEBS 26418 28-8-02
G. Velasco et al./FEBS Letters 527 (2002) 101^104102
pellets were denatured in SDS and the presence of PP1M or MBP-
MYPT1[714^1004] analysed by SDS^PAGE and immunoblotting.
3. Results and discussion
3.1. ROCK-II phosphorylates the MYPT1 subunit at Thr695
and Thr850
We used a constitutively active fragment of ROCK-II com-
prising residues 1^543 [16] to phosphorylate the PP1M com-
plex. Only the MYPT1 subunit, but not the M21 subunit or
the catalytic subunit, became phosphorylated (Fig. 1A). The
maximally phosphorylated PP1M was digested with trypsin
and chromatographed on a C18 column, which revealed a
single peak of 32P radioactivity (Fig. 1B) that was subjected
to mass spectrometry and Edman sequencing. These experi-
ments demonstrated the presence of two species correspond-
ing to monophosphorylated derivatives of the peptides
RSTQGVTLTDLQE and RSTGVSFWTQDSD, comprising
residues 693^705 and 848^860, respectively. Solid phase se-
quencing showed that the 32P radioactivity was only released
after the third cycle of Edman degradation (Fig. 1C). This
directly identi¢ed residues 697 and 850 as the sites of phos-
phorylation, which had previously been inferred from site-di-
rected mutagenesis experiments [15]. No phosphorylation of
Ser849 was detected in our experiments.
3.2. Phosphorylation by Rho kinase inhibits PP1M activity
The PP1M complex was phosphorylated by ROCK-II using
ATP[QS] to produce a thiophosphorylated derivative that
would be relatively resistant to autodephosphorylation by
the PP1 catalytic subunit. Under these conditions, there was
a time-dependent loss of PP1M activity when either the my-
osin P-light chain (Fig. 2A) or glycogen phosphorylase
(Fig. 2B) were used as substrates, which was abrogated in
the presence of Y27632, a relatively speci¢c inhibitor of
Rho kinase [17,18]. There was no inhibition of PP1M in con-
trol incubations where ATP[QS] was omitted.
The interaction of MYPT1 with PP1C is known to enhance
phosphatase activity towards myosin and suppress activity
towards glycogen phosphorylase [7]. As a consequence, the
dissociation of these subunits stimulates phosphorylase phos-
phatase but decreases myosin phosphatase activity. Therefore,
the ¢nding that the ROCK-II-catalysed phosphorylation of
PP1M inhibits phosphorylase phosphatase as well as myosin
phosphatase activity implies that inhibition of myosin phos-
phatase activity does not result from the dissociation of PP1C
and MYPT1. This is in contrast to the PKA-catalysed phos-
phorylation of PP1G, which triggers the dissociation of PP1C
from the GM subunit (see Section 1).
3.3. Phosphorylation on Thr850 triggers the dissociation of
PP1M from myosin
As reported previously [10], the PP1M complex bound to
myosin, but binding was greatly decreased after phosphoryla-
tion by ROCK-II (Fig. 3A). Interestingly, Thr850 lies within a
region that has been identi¢ed as a myosin-binding domain
[10]. In order to examine whether the failure of phosphorylat-
ed PP1M to bind to myosin resulted from the phosphoryla-
tion of MYPT1 at Thr850, the experiment was therefore re-
peated using a C-terminal myosin-binding fragment of
MYPT1 (expressed as a MBP fusion MBP-MYPT1[714^
1004]), which binds to myosin but lacks Thr695. Under the
conditions studied, densitometric scanning of the gels revealed
that 49% of the MBP-MYPT1[714^1004] was pelleted with
myosin, but this was decreased 22% after phosphorylation
by ROCK-II (Fig. 3B). Strikingly, the fraction of the MBP-
MYPT1[714^1004] that was phosphorylated at Thr850 did
not bind to myosin at all (Fig. 3C), demonstrating that phos-
phorylation of this residue is su⁄cient to abolish the binding
of the C-terminal fragment of MYPT1 to myosin. Similar
results were obtained in several independent experiments.
3.4. Concluding remarks
Earlier studies had indicated that the ROCK-II-catalysed
Fig. 2. Phosphorylation by ROCK-II inhibits PP1M activity. PP1M
was phosphorylated as described under Section 2 in the presence of
0.5 nM ROCK-II (open circles), 0.5 nM ROCK-II and 0.2 mM
ATP[QS] (closed circles), or 0.5 nM ROCK-II, 0.2 mM ATP[QS] and
50 WM Y27632 (closed triangles). Aliquots of the reactions were
taken at the times indicated, diluted in bu¡er A and assayed for
myosin light chain (MLC) phosphatase activity (A) or phosphory-
lase phosphatase activity (B). Results are presented as a percentage
of the activity measured in incubations in which ROCK-II and
ATP[QS] were omitted. A representative example of ¢ve separate ex-
periments is shown.
Fig. 3. Phosphorylation of PP1M and MYPT[714^1004] by ROCK-
II prevents binding to myosin. 1 nM PP1M (A) or 0.15 nM
MYPT1[714^1004] (B and C) were phosphorylated for 30 min at
30‡C with or without 1 WM myosin as described under Section 2
and centrifuged. The supernatant (S) and resuspended pellets (P)
were analysed by SDS^PAGE on 10% or 7.5% polyacrylamide gels,
transferred to nitrocellulose, and immunoblotted with antibodies
raised against the PP1M holoenzyme (A and B) or a phosphopep-
tide corresponding to the sequence surrounding Thr850 (C). A rep-
resentative experiment is shown for each panel. Similar results were
obtained in three independent experiments. No PP1M or
MYPT1[714^1004] were pelleted if myosin was omitted from the in-
cubations (data not shown).
FEBS 26418 28-8-02
G. Velasco et al./FEBS Letters 527 (2002) 101^104 103
phosphorylation of MYPT1 at Thr695 inhibits PP1M. In this
paper, we show that phosphorylation also prevents the bind-
ing of PP1M to myosin and that this is mediated, at least in
part, by the phosphorylation of Thr850, which is located in a
myosin-binding domain. The dissociation of PP1M from my-
osin may be a ‘failsafe’ device to prevent PP1M from dephos-
phorylating the myosin P-light chain in situations where the
phosphorylation of Thr695 is incomplete. It would therefore
be interesting to know the relative rates at which Thr695 or
Thr850 are phosphorylated and dephosphorylated in smooth
muscle during contraction and relaxation.
The presence of two phosphorylation sites on MYPT1 that
inhibit PP1M activity in di¡erent ways also raises the possi-
bility that these residues may be phosphorylated di¡erentially
by di¡erent protein kinases that respond to distinct signals. In
this connection, it should be noted that Thr695 can also be
phosphorylated in vitro by a Zip-like kinase associated with
PP1M [12,19,20].
Although we were unable to detect any phosphorylation of
chicken gizzard MYPT1 at Ser849 by ROCK-II (Fig. 1C),
others have reported that this residue is one of the major sites
phosphorylated by ROCK [21]. The reason for this discrep-
ancy is unclear, although one possibility is that it could be
related to their use of the isolated rat MYPT1 subunit as a
substrate, whereas we used the native PP1M complex isolated
from chicken gizzard. These investigators also reported that
stimulation of mammalian MDCK cells with tetradecanoyl-
phorbol-13-acetate triggered the phosphorylation of mamma-
lian MYPT1 at the residue equivalent to Ser849 of chicken
gizzard MYPT1 [21]. However, phosphorylation was only in-
hibited partially by pharmacological inhibitors of ROCK and
it remains possible that Ser849 is targeted by a di¡erent pro-
tein kinase(s) in cells. In these experiments, phosphorylation
of Ser849 correlated with an increase in the cytosolic distri-
bution of myosin phosphatase, suggesting that Ser849, like
Thr850, may also trigger the dissociation of PP1M from my-
osin and change its subcellular distribution.
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